Sarcoidosis
190
24
28
101
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
15 trials with published results (8%)
Research Maturity
101 completed trials (53% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.3%
12 terminated out of 190 trials
89.4%
+2.8% vs benchmark
11%
21 trials in Phase 3/4
15%
15 of 101 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 101 completed trials
Clinical Trials (190)
FAPI PET Imaging - An Exploratory Study
Cardiac Sarcoidosis Randomized Trial
Interstitial Lung Disease Research Unit Biobank
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis
Use of CXCL9 as a Biomarker of Acthar Efficacy
Mayo AVC Registry and Biobank
Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis
Virtual Patient Groups for Sarcoidosis Associated Fatigue
Corticosteroid Tapering in Sarcoidosis
Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia
Expand Pulmonary Rehabilitation to Other Chronic Respiratory Diseases Than COPD
Immunological Mechanisms in Sarcoidosis
MoMa Signature During Granulomatosis
Rheumatology Patient Registry and Biorepository
Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension
Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
Institutional Registry of Rare Diseases
Cell Free DNA in Cardiac Sarcoidosis